Study · In vitro (cells) · 2014
2 resultsCravedi P, Manrique J, Hanlon KE, Reid-Adam J, Brody J, Prathuangsuk P, Mehrotra A, Heeger PS
Journal of the American Society of Nephrology : JASN27 Mar 2014Cited by 50 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
2 results from studies that gave the peptide. No result from this study comes from people.
In activated T cells, the CD131 agonist peptide ARA290 did not alter T-cell proliferation.
In plain wordsIn lab tests with T cells, ARA290 did not change T-cell growth.
humann: not reported in source
Activated T cellsSource sentences
addition of a specific CD131 agonist peptide, ARA290, did not alter T-cell proliferation
In activated T cells, the CD131 agonist peptide ARA290 did not alter cytokine production.
In plain wordsIn lab tests with T cells, ARA290 did not change the production of immune signals called cytokines.
humann: not reported in source
Activated T cellsSource sentences
addition of a specific CD131 agonist peptide, ARA290, did not alter T-cell proliferation or cytokine production.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated